Please ensure Javascript is enabled for purposes of website accessibility

Prime Minister of Yemen’s Houthi Government Killed in Israeli Strike

3 days ago

Texas Gov. Greg Abbott Signs Law Redrawing Congressional Maps

4 days ago

US Air Force will Offer Military Funeral Honors to Slain Capitol Rioter

4 days ago

US Republican Senator Joni Ernst Will Not Run for Re-Election, CBS News Reports

4 days ago

Wall Street Falls as Dell, Nvidia Drive Tech Losses

4 days ago

US Denies Visas to Palestinian Officials Ahead of UN General Assembly

4 days ago

Minneapolis Children Revealed Courage, Absorbed Fear During Church Shooting

5 days ago

Ford Recalls Nearly 500,000 Vehicles Over Brake Fluid Leak

5 days ago

Fresno-Bound Passenger Says Delta Attendant Slapped Him, Seeks $20M

5 days ago
Experts Scramble, but New Virus Vaccine May Not Come in Time
gvw_ap_news
By Associated Press
Published 6 years ago on
February 7, 2020

Share

WASHINGTON — The flu-like virus that exploded from China has researchers worldwide once again scrambling to find a vaccine against a surprise health threat, with no guarantee one will arrive in time.
Just days after Chinese scientists shared the genetic map of the culprit coronavirus, researchers at the U.S. National Institutes of Health had engineered a possible key ingredient for a vaccine they hope to begin testing by April.
Scientists from Australia to France, along with a list of biotech and vaccine companies, jumped in the race, pursuing different types of inoculations.

“We have the technology now. It’s feasible from an engineering and biological standpoint.” Dr. Barney Graham, deputy director of the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center
And Texas researchers froze an experimental vaccine developed too late to fight an earlier coronavirus — SARS, or severe acute respiratory syndrome — but are pushing U.S. and Chinese authorities to give it a try this time around. Because the new virus is a close cousin of SARS, it just might protect, said Dr. Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital.
All that work is coming at lightning speed compared to past outbreaks. Yet many experts agree it still may take a year — if every step along the way goes well — for any vaccine to be ready for widespread use. That’s if it’s even needed by then.
Globally, more than 28,000 people are infected and the death toll climbed past 560. The overwhelming majority are in China, but more than 200 people with the illness have been reported in over two dozen other countries.
For now, health officials are isolating the sick to fight spread of the virus, which causes fever, cough and in severe cases pneumonia. With no specific treatment, some doctors also are experimenting with antiviral medicines developed for other conditions.
“Ours is already manufactured and could take off pretty quickly,” said Hotez, who created the earlier SARS vaccine with Texas Children’s colleague Maria Elena Bottazzi. But “there’s still no road map for what you do to make a vaccine in the midst of a devastating public health outbreak.”
NIH specialists say rather than chasing outbreaks, it’s time to pursue prototype vaccine designs that could work for entire virus families, ready to be pulled off the shelf at the first sign of a new disease.
“We have the technology now. It’s feasible from an engineering and biological standpoint,” said Dr. Barney Graham, deputy director of the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center. Without that step, “we’re going to be at risk for new pandemics.”
Photo of Pasteur Institute in Paris
View of the logo at Pasteur Institute in Paris, Thursday, Feb. 6, 2020. Scientists at the Pasteur Institute developed and shared a quick test for the new virus that is spreading worldwide, and are using genetic information about the coronavirus to develop a potential vaccine and treatments. (AP Photo/Francois Mori)

A Faster Vaccine Recipe

Traditionally, making vaccines required first growing lots of virus in a lab. The NIH team is pursuing a newer and far faster method: Simply use a piece of the virus’ genetic code, called messenger RNA or mRNA, that instructs cells to make a particular protein.
“We think of RNA as the software of life,” said Dr. Tal Zaks, chief medical officer of Moderna Inc., which is developing mRNA vaccines for other diseases and working with NIH on the new coronavirus.
Inject the right piece and “you’ve taught the body to make its own medicine,” he explained. As cells produce just that protein, the immune system learns to recognize it, primed to attack if the entire virus ever comes along.
The target: A protein aptly named “spike” that lets the virus bind to cells. It studs the surface of coronaviruses — the new one as well as its cousins SARS, which erupted in China in 2002 and spread to 26 countries, and MERS, or Middle East respiratory syndrome, which emerged in 2012.
Graham’s team zeroed in on the RNA responsible for the new virus’ production of spike and then — because prior research showed the protein can change shape — engineered a more stable version of it.
Moderna is manufacturing samples of the synthetic mRNA vaccine for NIH to use in animal studies and, hopefully within three months, first-stage safety tests in people. If further testing proves it really works, the hope is scientists could simply swap in a new spike code if another coronavirus comes along.
That’s important because after three such outbreaks in less than 20 years, “this is not the last,” predicted Dr. Mark Denison, a virologist at Vanderbilt University Medical Center. It’s key to find vaccine “strategies that go after these unique things common to every coronavirus.”

What Else Is in the Pipeline

Inovio Pharmaceuticals is pursuing a similar approach with synthetic DNA, and recently reported promising results from first-stage testing of a MERS vaccine. It’s collaborating with a Chinese company, Beijing Advaccine, in hopes of being able to test a new vaccine candidate in China later this year.

“The work we’re doing now involves making a vaccine against measles but re-engineered in the sense that it has antigens from the new coronavirus.” virologist Frederic Tangy, head of Pasteur’s vaccine innovation department
In France, researchers at the Pasteur Institute are piggybacking on the tried-and-true vaccine against measles. They’ve had some early success mixing genetic material from other viruses into that vaccine, and now hope to put the immune system on alert against this new coronavirus in the same way.
“The work we’re doing now involves making a vaccine against measles but re-engineered in the sense that it has antigens from the new coronavirus,” said virologist Frederic Tangy, head of Pasteur’s vaccine innovation department.
What about Hotez’s old SARS vaccine? In that case a piece of the spike protein was genetically engineered and grown in a lab, a classic vaccine technology compared to the newer and less proven Moderna and Inovio approaches. The Texas researchers showed the vaccine protected animals but in 2016 ran out of money for further testing and froze what was left. Every six months, Hotez thaws a small sample to make sure it’s still usable.
Photo of a scientist holding samples
Vincent Enouf, Deputy director of National Flu Center displays samples prior to put them into machine for analyze at Pasteur Institute in Paris, Thursday, Feb. 6, 2020. Scientists at the Pasteur Institute developed and shared a quick test for the new virus that is spreading worldwide, and are using genetic information about the coronavirus to develop a potential vaccine and treatments. (AP Photo/Francois Mori)French lab scientist in hazmat gear inserting liquid in test tube

Chasing Outbreaks

Past outbreaks are full of such missed opportunities: There’s no commercial vaccine for MERS even though illnesses still occur. The birth defect-causing Zika outbreak was ending by the time experimental shots were ready to test.
The bright spot: Ebola vaccines. Some candidates began early testing during the massive Ebola epidemic in West Africa in 2014-2016, although the outbreak waned before scientists had proof they worked. But authorities and vaccine companies kept up the research, and by 2018 shots were ready to help tamp down an outbreak still smoldering in Congo.
The World Health Organization will meet next week to identify promising drug and vaccine candidates for the new coronavirus and fast-track their development, much like happened with Ebola.
“To put it bluntly, we’re shadow boxing,” said WHO Director-General Tedros Adhanom Ghebreyesus. “We need to bring this shadow out into the light so that we can attack it properly.”

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Tulare County Authorities Investigate Porterville Shooting

DON'T MISS

Trump’s World Liberty Token Falls in First Day of Trading

DON'T MISS

Bessent Expects Supreme Court to Uphold Legality of Trump’s Tariffs but Eyes Plan B

DON'T MISS

Trump Says Rudy Giuliani Will Receive Top US Civilian Honor

DON'T MISS

Aid Flotilla for Gaza Departs Barcelona After Stormy Weather Turnaround

DON'T MISS

Fresno County Garnet Fire Grows to 18,748 Acres in Sierra National Forest

DON'T MISS

US Judge Blocks Deportations of Unaccompanied Migrant Children to Guatemala

DON'T MISS

Israel Pounds Gaza City Suburbs, Netanyahu to Convene Security Cabinet

DON'T MISS

Thousands in Australia March Against Immigration, Government Condemns Rally

DON'T MISS

Trump Says He Will Order Voter ID Requirement for Every Vote

UP NEXT

Aid Flotilla for Gaza Departs Barcelona After Stormy Weather Turnaround

UP NEXT

US Judge Blocks Deportations of Unaccompanied Migrant Children to Guatemala

UP NEXT

Israel Pounds Gaza City Suburbs, Netanyahu to Convene Security Cabinet

UP NEXT

Thousands in Australia March Against Immigration, Government Condemns Rally

UP NEXT

Trump Says He Will Order Voter ID Requirement for Every Vote

UP NEXT

Greta Thunberg Joins Flotilla Heading for Gaza With Aid

UP NEXT

Chicago Mayor Says Police Will Not Aid Federal Troops or Agents

UP NEXT

Post-War Gaza Plan Sees Relocation of Population, ‘Digital Token’ for Palestinian Land: Washington Post

UP NEXT

Judge Blocks Pillar of Trump’s Mass Deportation Campaign

UP NEXT

Dollar Trades Lower With Fed Cut In View, On Course For Monthly Drop

Trump Says Rudy Giuliani Will Receive Top US Civilian Honor

11 hours ago

Aid Flotilla for Gaza Departs Barcelona After Stormy Weather Turnaround

11 hours ago

Fresno County Garnet Fire Grows to 18,748 Acres in Sierra National Forest

2 days ago

US Judge Blocks Deportations of Unaccompanied Migrant Children to Guatemala

2 days ago

Israel Pounds Gaza City Suburbs, Netanyahu to Convene Security Cabinet

2 days ago

Thousands in Australia March Against Immigration, Government Condemns Rally

2 days ago

Trump Says He Will Order Voter ID Requirement for Every Vote

2 days ago

Greta Thunberg Joins Flotilla Heading for Gaza With Aid

2 days ago

Chicago Mayor Says Police Will Not Aid Federal Troops or Agents

2 days ago

Post-War Gaza Plan Sees Relocation of Population, ‘Digital Token’ for Palestinian Land: Washington Post

2 days ago

Tulare County Authorities Investigate Porterville Shooting

Tulare County sheriff’s deputies are investigating a shooting that left a man injured in Porterville on Monday afternoon. Deputies were call...

9 hours ago

A man was hospitalized after being shot Monday, Sept. 1, 2025, afternoon in Porterville, and Tulare County sheriff’s detectives are investigating. (Tulare County SO)
9 hours ago

Tulare County Authorities Investigate Porterville Shooting

Zach Witkoff, Co-Founder and CEO of World Liberty Financial, Donald Trump Jr. and Eric Trump pose before they ring the opening bell to celebrate the closing of ALT5’s $1.5 billion offering and adoption of its $WLFI Treasury Strategy at the Nasdaq Market, in New York City, U.S., August 13, 2025. (Reuters File)
9 hours ago

Trump’s World Liberty Token Falls in First Day of Trading

U.S. Secretary of the Treasury Scott Bessent pays his bill during a Labor Day visit to McLean Family Restaurant in McLean, Virginia, U.S., September 1, 2025. (Reuters/Brian Snyder)
9 hours ago

Bessent Expects Supreme Court to Uphold Legality of Trump’s Tariffs but Eyes Plan B

Former New York City Mayor and former lawyer for U.S. President-elect Donald Trump, Rudy Giuliani walks outside United States District Court in Manhattan, where a judge will consider a request by two Georgia election workers to whom he owes $148 million for defamation to hold him in civil contempt for failing to turn over his assets, in New York City, U.S., January 3, 2025. (Reuters File)
11 hours ago

Trump Says Rudy Giuliani Will Receive Top US Civilian Honor

Swedish activist Greta Thunberg departs with other activists on the Global Sumud Flotilla, a humanitarian expedition to Gaza, from the port of Barcelona, Spain August 31, 2025. The Sagrada Familia is seen in the background. (Reuters File)
11 hours ago

Aid Flotilla for Gaza Departs Barcelona After Stormy Weather Turnaround

Photo: USDA - Forest Service Tanker 40 at Fresno Air Attack Base. The Fresno County Garnet Fire in the Sierra National Forest has burned 18,748 acres and is 8% contained as crews make progress on containment lines while bracing for possible thunderstorms early this week. (Sam Wu/USFS)
2 days ago

Fresno County Garnet Fire Grows to 18,748 Acres in Sierra National Forest

U.S. flag and Judge gavel are seen in this illustration taken, August 6, 2024. (Reuters File)
2 days ago

US Judge Blocks Deportations of Unaccompanied Migrant Children to Guatemala

Smoke rises from Gaza after an explosion, as seen from the Israeli side of the border, August 31, 2025. (Reuters/Amir Cohen)
2 days ago

Israel Pounds Gaza City Suburbs, Netanyahu to Convene Security Cabinet

Search

Help continue the work that gets you the news that matters most.

Send this to a friend